Key market opportunities for SKYRIZI include its expansion across multiple indications such as psoriasis and IBD, showcasing best-in-class efficacy and strong clinical responses. Strategic positioning ...
While these patent cliffs are still some ways away, considering the time it takes to develop brand-new therapies, now is as good a time as any for AbbVie to start figuring out how it will overcome ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.’s ABBV SKYRIZI (risankizumab-rzaa) for children ...
AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the company's largest buyout in more than five years, as it seeks to bolster its treatment pipeline for inflammatory ...
AbbVie has won expanded European Commission approvals for its blockbuster autoimmune drug Skyrizi and its hepatitis C drug Maviret. AbbVie on Tuesday said Skyrizi is now approved in Europe for ...
AbbVie (ABBV) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque ...
NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI ® (risankizumab) for the treatment of children and ...
The European Commission approved AbbVie's SKYRIZI for pediatric patients aged six and older with moderate to severe plaque psoriasis. The market expansion introduces a new 55 mg pre-filled syringe ...
Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg 1 Nearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results